Answers are grounded in this paper and cite their sources.
Identifies microbial targets for preventing metabolic dysfunction–associated steatohepatitis, suggesting new therapeutic approaches.
Metabolic dysfunction–associated steatohepatitis (MASH) is increasingly linked to disruptions of the gut/liver axis, yet the microbial mechanisms driving disease progression remain incompletely defined. Here, Qu et al. have identified ileal microbial ammonia production by Clostridium perfringens as a mechanistic driver of epithelial barrier dysfunction and hepatic CD8 + T cell remodeling in MASH. In nonhuman primate and mouse models of MASH, the authors demonstrated that the glycine-based tripeptide DT-109 restored gut barrier integrity and attenuated FosB-mediated CCL5 expression in CD8 + T cells via inhibition of bacterial nitrite reductase A–mediated microbial ammonia production. These findings position microbial nitrogen metabolism as a tractable therapeutic target and highlight metabolite-focused microbiome interventions as a potential MASH intervention.
No takes yet. Share an insight, caveat, or question.
Leone et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: